<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166497">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916798</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 300</org_study_id>
    <nct_id>NCT01916798</nct_id>
  </id_info>
  <brief_title>Intralipid Therapy for Women 35-40 Years With Positive Natural Killer Cells Undergoing Intracytoplasmic Sperm Injection (ICSI)</brief_title>
  <official_title>Intravenous Intralipid Therapy Among Women Aged 35-40 Years With Positive Peripheral Blood Natural Killer Cells Undergoing in Vitro Fertilization-Embryo Transfer: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intralipid can suppress natural killer cells that are known to be involve in repeated
      implantation failure and recurrent miscarriages.Intralipid is made of purified soybean oil,
      egg phospholipids, glycerol and water. It provides essential fatty acids, linoleic acid,
      omega- 3 and 6 fatty acids and alpha-linolenic acid.   The effects of Intralipid in
      suppressing natural killer cell activity (NKa) were found to be comparable to intravenous
      immunoglobulin (IVIG) by laboratory experiments.We will study the effect of intralipid
      infusion on the pregnancy outcome of women aged 35-40 years with history of repeated
      implantation failure of miscarriage and who have positive peripheral blood natural killer
      cells
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intrauterine gestational sac with fatal pole and positive pulsation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>positive pregnancy test (serum BHCG) measured 16 days following embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of gestational sacs divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical pregnancy continue after 12 weeks gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Intralipid infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid infusion</intervention_name>
    <description>IV infusion of 250 ml of intralipid 20%  solution at the day of Ovum pick up &amp; another dose at the day of embryo Transfer.</description>
    <arm_group_label>Intralipid infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subfertile women aged 35-40 years with repeated implantation failure or recurrent
        miscarriage with positive natural killer cells undergoing Intracytoplasmic sperm injection
        (ICSI ) cycle.

        Exclusion Criteria:

          -  women above 40years or less than 35 years

          -  Disturbances of normal fat metabolism such as pathologic hyperlipidemia,Lipoid
             nephrosis or acute pancreatitis with hyperlipidemia.

          -  Allergic to eggs, soybean oil, or safflower oil.

          -  Severe liver disease, kidney disease, lung disease, anemia, blood coagulation
             disorder.

          -  Uterine fibroid, endometrial polyp, endometriosis and hydrosalpinx.

          -  Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies
             (Immunoglobulin G or M)[IgG or IgM]); other recognised thrombophilic conditions
             (testing according to usual clinic practice).

          -  Intrauterine abnormalities (as assessed by ultrasound, hysterosonography,
             hysterosalpingogram, or hysteroscopy).

          -  Fibroids distorting uterine cavity.

          -  Abnormal parental karyotype.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eman Elkattan, M.D,MRCOG</last_name>
    <phone>00201222854159</phone>
    <email>emyelkattan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eman Elkattan, M.D,M.R.C.O.G</last_name>
      <phone>00201222854159</phone>
      <email>emyelkattan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol. 2012 Apr;67(4):296-304. doi: 10.1111/j.1600-0897.2012.01111.x. Epub 2012 Feb 16. Review.</citation>
    <PMID>22340745</PMID>
  </reference>
  <reference>
    <citation>Shreeve N, Sadek K. Intralipid therapy for recurrent implantation failure: new hope or false dawn? J Reprod Immunol. 2012 Jan;93(1):38-40. doi: 10.1016/j.jri.2011.11.003. Epub 2011 Dec 21.</citation>
    <PMID>22196107</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 3, 2013</lastchanged_date>
  <firstreceived_date>August 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Eman Elkattan</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>intralipid</keyword>
  <keyword>invitro fertilization</keyword>
  <keyword>repeated implantation failure</keyword>
  <keyword>repeated miscarriage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
